Agregador de canales de noticias

Fibrilación auricular. A propósito de 2 casos [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Marc Roguera Sopena, Laura Sabidó Sánchez, Roger Villuendas Sabaté, Ricardo del Alcázar Muñoz
An Pediatr (Barc). 2020;92:47-9

Texto completo - PDF

Malformación linfática mesentérica: una causa poco frecuente de abdomen agudo [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Lara Merino Mateo, Rocío Morante Valverde, Jesús Vicente Redondo Sedano, María Isabel Benavent Gordo, Andrés Gómez Fraile
An Pediatr (Barc). 2020;92:49-51

Texto completo - PDF

Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2020 [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Francisco José Álvarez García, María José Cilleruelo Ortega, Javier Álvarez Aldeán, María Garcés-Sánchez, Nuria García Sánchez, Elisa Garrote Llanos, Ángel Hernández Merino, Antonio Iofrío de Arce, Manuel Merino Moína, Abián Montesdeoca Melián, María Luisa Navarro Gómez, Jesús Ruiz-Contreras

An Pediatr (Barc). 2020;92:52.e1-52.e10

Resumen - Texto completo - PDF

Neuroimagen en la encefalitis por virus Epstein-Barr [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Ana Reis-Melo, Marta Rosário, Cláudia Melo, Raquel Sousa
An Pediatr (Barc). 2020;92:53-4

Texto completo - PDF

Vulvovaginitis recurrente por cuerpo extraño oculto [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Pedro Mantas, Sara Rocha, Elisabete Oliveira, Aldina Lopes
An Pediatr (Barc). 2020;92:55-6

Texto completo - PDF

¿Vía accesoria aturdida o conducción intermitente? [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Marc Figueras-Coll, Anna Sabaté-Rotés, Ferran Rosés-Noguer, Jan Till
An Pediatr (Barc). 2020;92:57-9

Texto completo - PDF

¿Y si la oxigenoterapia de alto flujo no es el tratamiento idóneo para la bronquiolitis en las plantas de hospitalización? [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Susana Beatriz Reyes Domínguez, Pablo del Villar Guerra, Eider Oñate Vergara, María Miñambres Rodríguez
An Pediatr (Barc). 2020;92:60-1

Texto completo - PDF

La oxigenoterapia de alto flujo sí tiene un papel en el tratamiento de la bronquiolitis en las plantas de pediatría [Gratuito]

Anales Españoles de Pediatría - Jue, 02/01/2020 - 23:04
Felipe González Martínez, M. Isabel González Sánchez, Jimena Pérez Moreno, Rosa Rodríguez Fernández
An Pediatr (Barc). 2020;92:61-2

Texto completo - PDF

Hypertension and Neuroimaging Changes After Bevacizumab for Retinopathy of Prematurity

Pediatrics - Mié, 01/01/2020 - 10:01

Bevacizumab is a human monoclonal immunoglobulin G1 antibody to vascular endothelial growth factor indicated in several adult diseases. Emerging literature and expert opinion support the off-label use of intravitreal bevacizumab in the treatment of retinopathy of prematurity (ROP), a common disease process seen in premature neonates. One of the most common side effects of systemic therapy in adults is hypertension; however, this has not been well described in infants receiving bevacizumab for ROP. In this report, we review a case of a former 25-week premature infant treated for stage 3 ROP with administration of intravitreal bevacizumab. The immediate posttreatment course was uncomplicated; however, at 10 days posttreatment, he developed new-onset systemic hypertension. In addition, neuroimaging revealed new areas of vasogenic edema, which improved over time. To the best of our knowledge and after a review of the literature, neither of these effects has been described in neonates after intravitreal bevacizumab for ROP.

Interferon-{gamma} Release Assays in Children <15 Years of Age

Pediatrics - Mié, 01/01/2020 - 10:01
OBJECTIVES:

The tuberculin skin test (TST) has been preferred for screening young children for latent tuberculosis infection (LTBI) because of concerns that interferon- release assays (IGRAs) may be less sensitive in this high-risk population. In this study, we compared the predictive value of IGRAs to the TST for progression to tuberculosis disease in children, including those <5 years old.

METHODS:

Children <15 years old at risk for LTBI or progression to disease were tested with TST, QuantiFERON-TB Gold In-Tube test (QFT-GIT), and T-SPOT.TB test (T-SPOT) and followed actively for 2 years, then with registry matches, to identify incident disease.

RESULTS:

Of 3593 children enrolled September 2012 to April 2016, 92% were born outside the United States; 25% were <5 years old. Four children developed tuberculosis over a median 4.3 years of follow-up. Sensitivities for progression to disease for TST and IGRAs were low (50%–75%), with wide confidence intervals (CIs). Specificities for TST, QFT-GIT, and T-SPOT were 73.4% (95% CI: 71.9–74.8), 90.1% (95% CI: 89.1–91.1), and 92.9% (95% CI: 92.0–93.7), respectively. Positive and negative predictive values for TST, QFT-GIT, and T-SPOT were 0.2 (95% CI: 0.1–0.8), 0.9 (95% CI: 0.3–2.5), and 0.8 (95% CI: 0.2–2.9) and 99.9 (95% CI: 99.7–100), 100 (95% CI: 99.8–100), and 99.9 (95% CI: 99.8–100), respectively. Of 533 children with TST-positive, IGRA-negative results not treated for LTBI, including 54 children <2 years old, none developed disease.

CONCLUSIONS:

Although both types of tests poorly predict disease progression, IGRAs are no less predictive than the TST and offer high specificity and negative predictive values. Results from this study support the use of IGRAs for children, especially those who are not born in the United States.

Trends in Capability of Hospitals to Provide Definitive Acute Care for Children: 2008 to 2016

Pediatrics - Mié, 01/01/2020 - 10:01
BACKGROUND:

Provision of high-quality care to acutely ill and injured children is a challenge to US hospitals because many have low pediatric volume. Delineating national trends in definitive pediatric acute care would inform improvements in care.

METHODS:

We analyzed emergency department (ED) visits by children between 2008 and 2016 in the Nationwide Emergency Department Sample, a weighted sample of 20% of EDs nationally. For each hospital annually, we determined the Hospital Capability Index (HCI) to determine the frequency of definitive acute care, defined as hospitalization instead of ED transfer. Hospitals were classified annually according to 2008 HCI quartiles to understand shifts in pediatric capability.

RESULTS:

The national median HCI was 0.06 (interquartile range: 0.01–0.17) in 2008 and 0.02 (interquartile range: 0.00–0.09) in 2016 (P < .001). Definitive care became less common regardless of annual pediatric volume, urban or rural designation, or condition frequency. In 2016, 2171 EDs (49.0%) had HCIs <0.013, which represented the lowest 25% of ED HCIs in 2008. Pediatric visits to EDs categorized in the bottom 2008 capability quartile more than doubled from 2.5 million in 2008 to 5.3 million in 2016. Despite decreasing capability, centers with higher annual pediatric volume and urban centers provided more definitive inpatient care and had fewer inter-ED transfers than lower-volume and rural centers.

CONCLUSIONS:

Across the United States from 2008 to 2016, hospital provision of definitive acute pediatric care decreased, and ED visits to the hospitals least likely to provide definitive care increased. Systems improvements are needed to support hospital-based acute care of children.

Non-{beta}-Lactam Antibiotic Hypersensitivity Reactions

Pediatrics - Mié, 01/01/2020 - 10:01
OBJECTIVES:

Antibiotics are among the most common prescriptions in children, and non–β-lactam antibiotics (NBLAs) account for almost half of those prescribed in Australian pediatric hospitals. Despite this, data on NBLA hypersensitivity in children are limited. This study describes reported hypersensitivity reactions to NBLAs in children and the results of allergy evaluation.

METHODS:

Children with a suspected NBLA allergy who had skin testing and/or an intravenous or oral challenge test (OCT) between May 2011 and June 2018 were included. Patients were excluded if they were >18 years old or did not complete the allergy evaluation for any reason other than allergic reaction.

RESULTS:

Over the 7-year study period, 141 children had 150 allergy evaluations of 15 different NBLAs. The median time from the initial reported reaction to allergy evaluation was 1.9 (range 0.1–14.9) years. Overall, 27 of the 150 (18.0%) challenge tests to NBLAs had positive results, with the rate of positive OCT results being highest for trimethoprim-sulfamethoxazole (15 of 46; 32.6%) and macrolides (8 of 77; 10.4%). Although 4 children reported initial anaphylactic reactions, no patients had severe symptoms on rechallenge or required adrenaline. Of the challenges that had positive results, the majority of children (23 of 27; 85.2%) had symptoms on repeat challenge similar to those that were initially reported.

CONCLUSIONS:

Overall, 8 of 10 children with NBLA allergy could be delabeled. On average, patients waited 1.9 years to be rechallenged. Timely access to allergy evaluation to delabel these patients is needed to preserve first-line antibiotics.

Páginas